Carpro-AM1 is a compound that acts as a dual inhibitor of both fatty acid amide hydrolase (FAAH) and substrate-selective cyclooxygenase (COX). It exhibits potent inhibitory activity against FAAH, with an IC50 value of 94 nM [1].
AM-1714 is a reasonable selective agonist for the peripheral cannabinoid receptor CB2. In animal studies, it has been shown to have analgesic and anti-abnormal pain effects.